References
- Higgs G. A., Palmer R. M. J., Eakins K. E., Moncada S. Arachidonic acid metabolism as a source of inflammatory mediators and its inhibition as a mechanism of action for anti-inflammatory drugs. Molec Aspects Med 1981; 4: 275–301
- Samuelsson B., Borgeat P., Hammarström S., Murphy R. C. Introduction of a nomenclature: Leukotrienes. Prostaglandins 1979; 17: 785–7
- Belch J. J. F. The role of leukotrienes as mediators of inflammation. Advances in rheumatology, Vol. 4, J. M. H. Moll, R.D. Sturrock. Churchill Livingstone, London 1986; 37–51
- Klickstein L. B., Shapleigh C., Goetzl E. J. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 1980; 66: 1166–70
- Davidson E. M., Rae S. A., Smith M. J. H. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis 1983; 42: 677–9
- Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. R., Dalakos T. G., Greiveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: 393–406
- Ropes M. W., Bennett G. A., Cobb S., Jacox R., Jessar R. A. 1958 revision of diagnostic criteria of rheumatoid arthritis. Ann Rheum Dis 1959; 18: 49–51
- Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; 21: 77–82
- Salmon J. A., Simmons P. M., Palmer R. M. J. A radio-immunoassay for leukotriene B4. Prostaglandins 1982; 24: 225–35
- Udey M. C., Parker C. W. Effect of inhibitors of arachidonic acid metabolism on alpha amino-isobutyric acid transport in human lymphocytes. Biochem Pharmacol 1982; 31: 337–45
- Aldigier J. C., Gualde N., Mexmain S., Chable-Rabinovitch H., Atinaud M. H., Rigaud M. Immunosuppression induced in vivo by 15 hydroxyeicosatetraenoic acid (15HETE). Prostaglandins Leukotrienes Med 1984; 13: 99–107
- Bray M. A. The pharmacology and pathophysiology of leukotriene B4. Br Med Bull 1983; 39: 349–54
- Williams T. J. Interactions between prostaglandins, leukotrienes and other mediators of inflammation. Br Med Bull 1983; 39: 239, 2.
- Henderson W. R., Klebanoff S. J. Leukotriene production and inactivation by normal, chronic granulomatous disease and myeloperoxidase-deficient neutrophils. J Biol Chem 1983; 258: 522–7
- Dinarello C. A., Bishae I., Rosenwasser C. J., Coceani F. The influence of lipoxygenase inhibitors on the in-vitro production of human leukocytic pyrogen and lymphocyte activating factor (Interleu-kin-1). Int J Immunopharm 1984; 6: 43–50
- Belch J. J. F., Ansell D., Madhok R., O'Dowd A., Sturrock R. D. The effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A double-blind placebo controlled study. Ann Rheum Dis 1988; 47: 96–104
- Voorlees J. J. Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses. Arch Dermatol 1983; 119: 541–7
- Prescott S. M. The effect of eicosapentaenoic acid on leukotriene B4 production by human neutrophils. J Biol Chem 1984; 259: 7615–21
- Kremer J. M., Biganoette J., Michalek A. V., Timchalk M. A., Lininger L., Rynes I. R., Huych C., Zieminski J., Bartholomew L. E. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1985; i: 184–7
- Higgs G. A., Flower R. J. Anti-inflammatory drugs and the inhibition of arachidonate lipoxygenase. SRS-A and leukotrienes, J.A. Piper. Wiley & Sons, London 1981; 197–207